| Literature DB >> 24647992 |
Kiyoshi Koizumi, Hidekazu Masaki, Hiroshi Matsuda, Mayuki Uchiyama, Mitsuo Okuno, Eiji Oguma, Hiroshi Onuma, Kimio Kanegawa, Shinichi Kanaya, Hiroshi Kamiyama, Kensuke Karasawa, Masayuki Kitamura, Tetsuo Kida, Tatsuo Kono, Chisato Kondo, Masayuki Sasaki, Hitoshi Terada, Atsushi Nakanishi, Teisuke Hashimoto, Hiroshi Hataya, Shin-ichiro Hamano, Keishi Hirono, Yukihiko Fujita, Ken Hoshino, Masayuki Yano, Seiichi Watanabe.
Abstract
The Japanese Society of Nuclear Medicine has recently published the consensus guidelines for pediatric nuclear medicine. This article is the English version of the guidelines. Part 1 proposes the dose optimization in pediatric nuclear medicine studies. Part 2 comprehensively discusses imaging techniques for the appropriate conduct of pediatric nuclear medicine procedures, considering the characteristics of imaging in children.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24647992 PMCID: PMC4061477 DOI: 10.1007/s12149-014-0826-9
Source DB: PubMed Journal: Ann Nucl Med ISSN: 0914-7187 Impact factor: 2.668
Class and baseline activity/minimum activity of radiopharmaceuticals
| Nuclides | Radiopharmaceutical | Class | Doses | |
|---|---|---|---|---|
| Baseline activity (MBq) | Minimum activity (MBq) | |||
| I-123 | NaI | C | 0.6 | 3 |
| IMP | B | 13.0 | 18 | |
| MIBG (tumors) | B | 28.0 | 40 | |
| MIBG (myocardium) | B | 7.9 | 16 | |
| Iomazenil | B | 11.9 | 24 | |
| BMIPP | B | 7.9 | 16 | |
| F-18 | FDG | B | 14.0 | 14 |
| Ga-67 | Citrate | B | 5.6 | 10 |
| Tc-99m | Albumin (cardiac pool) | B | 56.0 | 80 |
| Tin colloid (liver and spleen) | B | 5.6 | 15 | |
| Tin colloid (bone marrow) | B | 21.0 | 20 | |
| Phytate (liver and spleen) | B | 5.6 | 15 | |
| MDP/HMDP | B | 35.0 | 40 | |
| DMSA | A | 25.6 | 15 | |
| DTPA | A | 34.0 | 20 | |
| MAG3 | A | 34.0 | 20 | |
| ECD | B | 32.0 | 110 | |
| HMPAO | B | 51.8 | 100 | |
| PMT | B | 10.5 | 20 | |
| MAA | B | 13.2 | 10 | |
| Pertechnetate (thyroid) | B | 5.6 | 10 | |
| Pertechnetate (gastric mucosa) | B | 10.5 | 20 | |
| RBC | B | 56.0 | 80 | |
| MIBI/tetrofosmin (tumors) | B | 63.0 | 80 | |
| MIBI/tetrofosmin (myocardial rest/stress scan 2-day protocol maxa) | B | 63.0 | 80 | |
| MIBI/tetrofosmin (myocardial scan 1-day protocol firstb) | B | 28.0 | 80 | |
| MIBI/tetrofosmin (myocardial scan 1-day protocol secondb) | B | 84.0 | 160 | |
| GSA | B | 13.2 | 26 | |
| Tl-201 | Thallium chloride (tumors) | B | 5.3 | 11 |
| In-111 | Indium chloride | B | 5.3 | 11 |
aAn excessive dose may be calculated of a heavy patient compared to the conventionally administered dose; therefore, a smaller dose should be considered since this dose is the maximum
bBoth the rest first and the stress first protocols are applicable. The second dose is two to three times the first dose
Weight-dependent multiples for each class
| Body weight (kg) | Class | ||
|---|---|---|---|
| A | B | C | |
| 3 | 1 | 1 | 1 |
| 4 | 1.12 | 1.14 | 1.33 |
| 6 | 1.47 | 1.71 | 2 |
| 8 | 1.71 | 2.14 | 3 |
| 10 | 1.94 | 2.71 | 3.67 |
| 12 | 2.18 | 3.14 | 4.67 |
| 14 | 2.35 | 3.57 | 5.67 |
| 16 | 2.53 | 4 | 6.33 |
| 18 | 2.71 | 4.43 | 7.33 |
| 20 | 2.88 | 4.86 | 8.33 |
| 22 | 3.06 | 5.29 | 9.33 |
| 24 | 3.18 | 5.71 | 10 |
| 26 | 3.35 | 6.14 | 11 |
| 28 | 3.47 | 6.43 | 12 |
| 30 | 3.65 | 6.86 | 13 |
| 32 | 3.77 | 7.29 | 14 |
| 34 | 3.88 | 7.72 | 15 |
| 36 | 4 | 8 | 16 |
| 38 | 4.18 | 8.43 | 17 |
| 40 | 4.29 | 8.86 | 18 |
| 42 | 4.41 | 9.14 | 19 |
| 44 | 4.53 | 9.57 | 20 |
| 46 | 4.65 | 10 | 21 |
| 48 | 4.77 | 10.29 | 22 |
| 50 | 4.88 | 10.71 | 23 |
| 52–54 | 5 | 11.29 | 24.67 |
| 56–58 | 5.24 | 12 | 26.67 |
| 60–62 | 5.47 | 12.71 | 28.67 |
| 64–66 | 5.65 | 13.43 | 31 |
| 68 | 5.77 | 14 | 32.33 |